Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848107 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of Oral Treprostinil in Digital Ulcers
A Phase 2 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00848107 is a Phase 2 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 115 participants.
The verdict
NCT00848107, a Phase 2 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects with SSc and digital ulcers.
Interventions
- DRUG treprostinil diethanolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848107
The ClinicalTrials.gov registry entry for NCT00848107 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which treprostinil diethanolamine is the first listed.
NCT00848107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00848107 about?
NCT00848107 is a clinical study titled "Open-Label Study of Oral Treprostinil in Digital Ulcers". This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects with SSc and digital ulcers.
What is the current status of trial NCT00848107?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2009-09. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00848107?
The interventions under investigation include: treprostinil diethanolamine (DRUG).
Who is sponsoring clinical trial NCT00848107?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.